Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H26NO3.Br |
Molecular Weight | 420.34 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].C[N+]1(C)CCCC(C1)OC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=JRRNZNSGDSFFIR-UHFFFAOYSA-M
InChI=1S/C21H26NO3.BrH/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18;/h3-8,10-13,19,24H,9,14-16H2,1-2H3;1H/q+1;/p-1
Mepenzolate is a postganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. It specifically antagonizes muscarinic receptors. Mepenzolate is marketed under the brand name CANTIL. CANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been
shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or
preventing complications.
CNS Activity
Sources: http://www.pdr.net/drug-summary/Cantil-mepenzolate-bromide-1899 | https://livertox.nih.gov/Mepenzolate.htm
Curator's Comment: Similar to other quaternary ammonium anticholinergics, mepenzolate has limited ability to cross lipid membranes, such as the blood-brain barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 |
2.6 nM [Ki] | ||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24844758 |
0.68 nM [Ki] | ||
Target ID: CHEMBL216 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CANTIL Approved UseCANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. Launch Date1956 |
Doses
Dose | Population | Adverse events |
---|---|---|
750 mg single, oral Highest recorded dose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: |
unhealthy, 30 years n = 1 Health Status: unhealthy Age Group: 30 years Population Size: 1 Sources: |
Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: |
500 mg single, oral Highest recorded dose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Adverse event | grade 5 | 750 mg single, oral Highest recorded dose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: |
unhealthy, 30 years n = 1 Health Status: unhealthy Age Group: 30 years Population Size: 1 Sources: |
Sample Use Guides
The usual adult dose is 1 or 2 tablets (25 or 50 mg) 4 times a day preferably with meals and at bedtime.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7623487
Mepenzolate (10(-8)-10(-5) M), a specific muscarinic receptor antagonist, antagonized contractions of the longitudinal muscle of the isolated guinea-pig ileum preparation elicited by the aqueous extracts of Mareya micrantha suggesting that the cholinergic ingredient(s) in the extract are acting at the muscarinic receptors of the preparation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08745MIG
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
100000081495
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
37717-96-7
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
ALTERNATIVE | |||
|
52560
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-992-7
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
6461
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
APX8D32IX1
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
C61829
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
76-90-4
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
DBSALT000451
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
m7185
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
4358
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
DTXSID4023252
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
889
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL524004
Created by
admin on Fri Dec 15 16:03:28 GMT 2023 , Edited by admin on Fri Dec 15 16:03:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD